Félix J. Richmond Ryan Evans Squires

102 SCIENTIFIC SESSIONS September 9-12 | G-875 Protection against Experimental Aspergillosis by Heat-Killed Yeast HKY is not Antibody Dependent

V. Chen

1 , M. Martinez 1 , M. Liu 1,2,3 , H. Yun 1,3 , K. V. Clemons 1,2,3 , D. A. Stevens 1,2,3 ; 1 California Inst. for Med. Res., San Jose, CA, 2 Santa Clara Vly. Med. Ctr., San Jose, CA, 3 Stanford Univ., Stanford, CA. G-876 Genome-Wide Association Study Identifies Variants Near IFNW1 and IFNB1 Associated with Host Susceptibility to Pneu- mococcal Disease

T. Benfield

1 , M. Nørgaard 2 , M. Hollegaard 3 , L. N. Clausen 1 , H. T. Sørensen 2 , H. M. David 3 , H. B. Konradsen 3 , Z. B. Harboe 1 ; 1 Copenhagen Univ. Hosp., Hvidovre, Denmark, 2 Århus Univ., Århus, Denmark, 3 Staten Serum Inst., Copenhagen, Denmark. Late-breaker presentations are listed behind the Late-breaker tab of the Final Program. ------------------------------------------------------------------------ 102 H Poster Session Antiretroviral Therapy Outcomes Including Select Populations Monday, 11:15 a.m.–1:15 p.m. . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: H-877 Long-Term 96 And 144 Week Efficacy and Safety from the Verxve Trial Comparing Nevirapine Extended Release NVP XR 400 Mg Once a Day qd to Nevirapine Immediate Release NVP IR 200 Mg Twice a Day bid in Combination with Emtric- itabineTenofovir in Treatment-Naïve HIV-1 Patients C. Brinson 1 , A. Quinson 2 , M. Drulak 2 , J. Gathe, Jr. 3 ; 1 Central Texas Clini- cal Res.,, Austin, TX, 2 Boehringer Ingelheim, Ridgefield, CT, 3 Therapeutic Concepts, Houston, TX. H-878 Efficacy and Tolerability of TenofovirEmtricitabine Versus Abacavirlamivudine Based Antiretroviral Treatment for NaïVe HIV-1 Infected Patients: A Mixed Treatment Comparison

J. Félix

1 , B. Vandewalle 1 , S. Rabiais 1 , M. J. Silva 1 , D. Ferreira 1 , J. Almeida 1 , E. Teófilo 2 ; 1 Exigo, Alhos Vedros, Portugal, 2 Centro Hosp. Lisboa Central, Hosp. dos Capuchos, Lisboa, Portugal. H-879 ElvitegravirCobicistatEmtricitabineTenofovir DF Quad Demonstrates Comparable Efficacy and Favorable Tolerability to EfavirenzEmtricitabine Tenofovir DF in Patients 50 Years

G. J. Richmond

1 , P. Ruane 2 , W. Robbins, F 3 , U. Bredeek 4 , P. Shalit 5 , D. Hardy 6 , K. Workowski 7 , M. Rhee 8 , D. Piontkowsky, JD 8 ; 1 Gary Richmond MD PA, Fort Lauderdale, FL, 2 Peter Ruane MD Inc., Los Angeles, CA, 3 Value Hlth. MD, Orlando, FL, 4 Metropolis Med., San Francisco, CA, 5 Tribal Med, Seattle, WA, 6 Cedars-Sinai Med. Ctr., Los Angeles, CA, 7 Emory Clinic, Atlanta, GA, 8 Gilead Sci., Foster City, CA. H-880 Older Patients Showed Similar Efficacy and Safety Results Compared to Younger Participants Over 96 Weeks in the Phase III ECHO and THRIVE Trials of Treatment-Naive HIV-1- Infected Patients Treated with Rilpivirine or Efavirenz

R. Ryan

1 , Y. Dayaram 2 , D. Schaible 2 , B. Coate 1 , D. Anderson 2 ; 1 Janssen Res. Dev., Titusville, NJ, 2 Janssen Services, LLC, Titusville, NJ. H-881 Meta Analysis of Differences in Viral Suppression by Race in Clinical Trials

C. Evans

1 , H. Kwakwa 2 , D. Spencer 3 , L. Temme 4 , I. Walker 4 , M. Rawlings 4 ; 1 AIDS ARMS, Dallas, TX, 2 Philadelphia Dept. of Publ. Health, Philadel- phia, PA, 3 Univ. of Maryland Sch. of Med., Baltimore, MD, 4 Gilead Sci., Inc., Foster City, CA. H-882 Gender Stratification Analysis of HIV-1 Infected Patients Receiving Atazanavir ATV Compared to ATVRitonavir RTV, Each in Combination with AbacavirLamivudine ABC3TC, after Initial Suppression with ABC3TC + ATVRTV Through 144 Weeks on Therapy

K. Squires

1 , B. Young 2 , L. Santiago 3 , R. Dretler 4 , S. Walmsley 5 , H. Zhao 6 , B. Wine 6 , L. L. Ross 6 , M. Shaefer 7 ; 1 T. Jefferson Univ, Philadelphia, PA, 2 Univ. of Colorado, Denver, Colorado, 3 HOPE Clin Res, San Juan, Puerto Rico, 4 ID Specialists of Atlanta, Decatur, GA, 5 Univ Hlth. Network, Toronto, Canada, 6 GlaxoSmithKline, Research Triangle Park, NC, 7 ViiV Healthcare, Research Triangle Park, NC. H-883 Efficacy and Use of PI vs EFV in Treatment Naive HIV+ Men and Women

J. Patel